| Document |
Document Title |
|
WO/2022/168884A1 |
The present invention provides a novel cationic lipid having excellent encapsulation and delivery stability of nucleic acid medicines. Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof. (In ...
|
|
WO/2022/167866A1 |
The present disclosure relates in part to chemical modulators of protein phosphatase 2A (PP2A), comprising formula (I). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, aut...
|
|
WO/2021/188728A9 |
The invention relates generally to novel EPAC1 activators, such as Formula (I) and (II) and the preparation thereof as well as the use of EPAC1 activators disclosed herein as to selectively activate EPAC1 in cells.
|
|
WO/2022/161416A1 |
Disclosed are an aromatic compound represented by formula I, and a pharmaceutically acceptable salt, stereoisomer, tautomer, or isotopic compound thereof. The compound has high P2X4 antagonistic activity, good safety, and good pharmacoki...
|
|
WO/2022/162083A1 |
A polymer film comprising anionic groups and 0.008 to 25mg/g of each of components (a) and (b): (a) a crosslinking agent which is free from fluoro groups and comprises a group of Formula (I); and (b) a non-ionic crosslinking agent; Formu...
|
|
WO/2022/150461A1 |
The present disclosure relates to methods of treating a ciliopathy, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound or pharmaceutical composition thereof, wherein the comp...
|
|
WO/2022/149617A1 |
The present invention provides a library which comprises from 1 × 102 to 1 × 108 compounds; the compounds have a structure in which a first core block (first CB), a first linker (first L) and a second core block (second CB) are covalen...
|
|
WO/2022/138931A1 |
Provided is a compound represented by general formula (B1). Also provided is a corrosion inhibitor (B) including one or more selected from compounds represented by general formula (B1). Further provided is a lubricant composition includi...
|
|
WO/2022/133027A1 |
Compounds of formula (1) wherein R1 represents a -C(R2)(R3)-[C(R4)(R5)]m-L-R6 group or -R7; and the preparation and the therapeutic uses of the compounds of formula (1) as agonists of TRPM8 receptors, useful especially in the treatment o...
|
|
WO/2022/129125A1 |
The present invention related to compounds of Formula (I):(I) or an agronomically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 are as described herein. The invention further relates to compositions comprising said compounds, to...
|
|
WO/2022/118277A1 |
This invention relates to a field of novel multi-headed compounds capable of binding and inhibiting the catalytic activity of human carbonic anhydrases for diagnostic, visualization, and treatment purposes. A series of compounds containi...
|
|
WO/2022/120353A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2022/116714A1 |
Provided in the present application are a compound and the medical use thereof for novel coronavirus pneumonia, which belongs to the technical field of pharmaceuticals. The compound is a compound represented by formula I or formula II, o...
|
|
WO/2022/093716A1 |
Electrode or electrolyte additives for energy storage devices comprising symmetrical or asymmetrical alkylsulfonyl imide or cyclic alkylene sulfonylimide salts are disclosed. The energy storage device comprises a first electrode and a se...
|
|
WO/2022/090448A1 |
The present invention relates to a novel acylating reagent, a method for its preparation, and a method of using it for acylating at the N-terminal of a peptide or a protein. The novel acylating reagent may be a compound which comprises 5...
|
|
WO/2022/069385A1 |
A polymer film obtainable by curing a composition comprising a compound of Formula (I) wherein: R' is vinyl, epoxy or C1-3-alkylenethiol: n has a value of 1 or 2; m has a value of 1, 2 or 3; M'+ is a cation; wherein X is as defined in th...
|
|
WO/2022/047288A9 |
Phenylsulfonamido compounds that inhibit genome-wide hypomethylation and can be used to treat cancer, including melanoma, prostate cancer, pancreatic cancer, breast cancer, colon cancer, lung cancer, ovarian cancer, and glioblastoma, are...
|
|
WO/2022/066678A1 |
The present invention provides, in part, TES-based lipid compounds of Formula (la), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA ...
|
|
WO/2022/060969A1 |
The present disclosure generally relates to pharmaceutical compositions and combinations comprising N-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl)propa
n-2-yl)phenoxy) methyl)pyrimidin-2-yl)methanesulfonamideN-(4-((4-(2-(3-chlor...
|
|
WO/2022/056369A2 |
Described herein are compounds and compositions for use in treatment or prevention of an inflammatory bowel disease, gastrointestinal cancer, or a systemic bacterial infection in a subject in need thereof. The subject may be colonized by...
|
|
WO/2022/051639A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for the inhibition of Signal Transducer and Activator of Transcription 5a and 5b (STAT5). Furthermore, the subject compounds and comp...
|
|
WO/2022/050803A1 |
The present invention relates to a metastasis-inhibiting composition containing a methylsulfonamide-based derivative compound as an active ingredient. More specifically, the compounds of the present invention inhibit the activity of chro...
|
|
WO/2022/043374A1 |
The present invention relates to compounds of formula (II) wherein R1-R5, X and L are as described herein, and pharmaceutically acceptable salts thereof, compositions including the compounds and methods of using the compounds, particular...
|
|
WO/2022/038224A1 |
A method for the preparation of an alpha-substituted carbonyl compound or an alpha- substituted nitrile compound carrying an aryl or heteroaryl group as an alpha-substituent, said method comprising reacting a sulfoxide compound S1 compri...
|
|
WO/2022/038359A1 |
The invention relates to a vinyl disulfone compound of general formula (I) In which X, which may be present or absent, is an organic moiety comprising from 1 to 16 carbon atoms; Y is a fluorophore or biomolecule; R1 is an organic moiety ...
|
|
WO/2022/038561A1 |
Methods of producing N,N-branched sulfamoyl fluoride compounds of the formula F-S(O)2-NR2 by contacting bismuth trifluoride with an N,N-branched sulfamoyl nonfluorohalide compound of the formula X-SO2NR2, wherein X = chlorine (C1), bromi...
|
|
WO/2022/035804A1 |
The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof and pharmaceutical composition comprising the compound of formula (I). The present composition also relates to methods treating a d...
|
|
WO/2022/030107A1 |
The purpose of the present invention is to provide: a photoacid generator containing a sulfonamide compound which has a high decomposition rate in response to near-ultraviolet rays, generates a superacid bis-sulfonamide, and is highly so...
|
|
WO/2022/027122A1 |
The present invention is related to compositions containing only natural products for the treatment of erectile and sexual dysfunction (ESD). More specifically relates to compositions containing Cannabis extract, and other herbal extract...
|
|
WO/2022/027953A1 |
Disclosed is the use of C188-9, Venetoclax, and Bumetanide in a drug for fibrotic diseases. From a clinical view, an RNA recognition motif (RRM) region of the LARP6 protein is used as a docking target, and is subjected to computer virtua...
|
|
WO/2022/025117A1 |
The present invention provides the compound represented in general formula (A1) [Ar1 is a C6-14 aryl group or a C5-14 nitrogen-containing heteroaryl group, substituted with at least two electron-attracting groups; R1 is a C1-30 alkyl gro...
|
|
WO/2022/018462A1 |
The invention further relates to said compounds for use as a medicament, for use in the prevention of DNA damage, and/or for use in the treatment or prevention of a disease associated with iron induced oxidative stress. This invention re...
|
|
WO/2022/012666A1 |
The present invention relates to a sulfonylurea derivative and medical uses thereof, specifically relating to the sulfonylurea derivative shown in general formula (I), a preparation method thereof, a pharmaceutical composition containing...
|
|
WO/2022/008283A1 |
The present invention to a group of compounds of formula (I) useful for the transfer of polyfluoroalkylthiol groups of at least two carbons atoms into a great variety of organic compounds as well as to the process for their preparation. ...
|
|
WO/2022/000443A1 |
Provided herein are compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.
|
|
WO/2022/004673A1 |
Provided are: a compound having excellent effect against various pests, and an intermediate of the compound; an agricultural and horticultural agent utilizing the compound; a method for producing the compound or the intermediate; and a m...
|
|
WO/2022/006392A1 |
The present disclosure relates to novel pharmaceutical compositions for active pharmaceutical ingredients subject to first pass metabolism. More particularly, bumetanide analogs, including bumetanide dibenzylamide, bumetanide diethylamid...
|
|
WO/2021/257544A1 |
Disclosed are compounds that are chemical inhibitors of SOX11. The compounds disclosed are useful in treatment of various cancers.
|
|
WO/2021/251086A1 |
A first problem addressed by the present invention is to provide an active-ray-sensitive or radiation-sensitive resin composition with which a pattern having a favorable form can be obtained. Further, a second problem addressed by the pr...
|
|
WO/2021/244463A1 |
Provided in the present invention are/is a small-molecule inhibitor targeting an EB virus nuclear antigen protein and/or a pharmaceutical composition containing same, which can be used for the treatment of diseases caused by EBNA1 activi...
|
|
WO/2021/243446A1 |
A dry contact disinfectant includes a mixture of a powdered carrier and a powdered disinfectant. The powdered carrier has beneficial properties for a predetermined activity, and the powdered disinfectant is effective for killing one or m...
|
|
WO/2021/246779A1 |
The present invention relates to an amide derivative synthesized using probenecid and arginine as reactants, a pharmaceutical composition comprising same for preventing, ameliorating, or treating heart failure, and a method for synthesiz...
|
|
WO/2021/243319A1 |
Provided herein are a biarylsulfonamide, e.g., a compound of Formula (IA), and a pharmaceutical composition thereof. Also provided herein is a method of treating a fibrotic lung disease with a biarylsulfonamide, alone or in combination w...
|
|
WO/2021/241725A1 |
The present invention addresses the problem of providing N-(5-methoxy-2-phenoxyphenyl)methanesulfonamide with a reduced amount of impurities; and a method for producing the same. According to the present invention, provided are: N-(5-met...
|
|
WO/2021/226675A1 |
The invention provides a zwitterionic plastic crystal (ZIPC) compound in the form of a single molecule comprising: at least one positively charged functional group carrying at least one positive charge, and at least one negatively functi...
|
|
WO/2021/226149A1 |
Provided herein are a method of Ru(II)-catalyzed enantioselective synthesis of a cyclic compound and cyclic compounds formed therefrom. The method includes providing a precursor compound having an unfunctionalized C-H bond and activating...
|
|
WO/2021/225833A1 |
Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound Z that can be used to prepare them. In particular, provided herein are processes for synthesizing compound A1, and salts or solvates there...
|
|
WO/2021/221445A1 |
This specification relates to a compound as a UBR box domain ligand. The present specification provides a small molecule compound that binds to a UBR box domain. In addition, the present specification provides a composition for inhibitin...
|
|
WO/2021/201054A1 |
This non-aqueous electrolyte for batteries contains a phosphazene compound (A) including at least one among a phosphazene compound represented by formula (1) and a phosphazene compound represented by formula (2). In formulae (1) and (2),...
|
|
WO/2021/200179A1 |
The present invention provides an actinic-ray-sensitive or radiation-sensitive resin composition comprising (A) a resin which increases in polarity by the action of an acid and (B) a compound which generates an acid upon irradiation with...
|
